MonarQ TTVR System
Tricuspid Regurgitation
Global Clinical TrialFirst-in-human completed
Key Facts
Indication
Tricuspid Regurgitation
Phase
Global Clinical Trial
Status
First-in-human completed
Company
About Peijia Medical
A leading Chinese medtech company developing innovative transcatheter heart valve and neurointerventional devices for structural heart disease and stroke.
View full company profileTherapeutic Areas
Other Tricuspid Regurgitation Drugs
| Drug | Company | Phase |
|---|---|---|
| MIA-T Percutaneous Tricuspid Annuloplasty System | Micro Interventional Devices | Clinical Trial |
| Tricuspid Valve Repair System | Abbott | Clinical Investigation |